Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study

Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study

Background: There are no randomized trials comparing andexanet alfa and 4 factor prothrombin complex concentrate (4F-PCC) for the treatment of factor Xa inhibitor (FXa-I)-associated bleeds, and observational studies lack important patient characteristics. We pursued this study to demonstrate the fea...

Full description

Bibliographic Details
Main Authors: Adam J. Singer, Mauricio Concha, James Williams, Caitlin S. Brown, Rafael Fernandes, Henry C. Thode Jr., Marylin Kirchman, Alejandro A. Rabinstein
Format: Article
Language:English
Published: eScholarship Publishing, University of California 2023-08-01
Series:Western Journal of Emergency Medicine
Online Access:https://escholarship.org/uc/item/5hf50287

Internet

https://escholarship.org/uc/item/5hf50287

Similar Items